Search

Hutchison China MediTech Ltd ADR

Chiusa

SettoreSettore sanitario

13.36 -1.33

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

13.31

Massimo

13.73

Metriche Chiave

By Trading Economics

Entrata

-8.9M

-8M

Vendite

3.7M

139M

P/E

Media del settore

136.6

56.432

Margine di Profitto

-5.724

Dipendenti

1,790

EBITDA

18M

4M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+18.35% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

462M

2.4B

Apertura precedente

14.69

Chiusura precedente

13.36

Notizie sul Sentiment di mercato

By Acuity

50%

50%

129 / 339 Classifica in Healthcare

Hutchison China MediTech Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

15 set 2026, 23:56 UTC

News

Lululemon Athletica shares are lower in after-market hours amid an investigation into potential securities law violations following a revenue guidance cut.

15 set 2026, 23:41 UTC

Correlated Moves
News

Heartland Express shares are lower in after-market trading, influenced by declines in Schneider National and concerns from the New York Empire State Manufacturing Index.

15 set 2026, 23:41 UTC

Correlated Moves
News

Tower Semiconductor shares are lower in after-market hours amid broader market dynamics and rising treasury yields ahead of the Federal Reserve's policy decision.

15 set 2026, 23:31 UTC

News

Xylem Inc. shares declined in after-market hours following a $1.5 billion senior notes offering, reflecting broader market trends and shifting investor sentiment.

15 set 2026, 23:26 UTC

News

Phil Poliquin has been appointed senior vice president at United Bankshares, focusing on government contracting. Shares are roughly flat in after-market trading.

15 set 2026, 23:16 UTC

News

FedEx shares are lower in after-market trading following the appointment of Mike Rodgers as Chief Commercial and Technology Officer amid broader market pressure.

15 set 2026, 23:16 UTC

News

Royalty Pharma announced a $7.5 million donation to Blood Cancer United. Shares are lower in after-market trading amid rising Treasury yields.

15 set 2026, 23:11 UTC

News

Coca-Cola Europacific Partners PLC gains in after-market hours on a planned $10 billion investment in U.S. infrastructure through 2030, focusing on production and distribution.

15 set 2026, 23:06 UTC

News

FuelCell Energy shares rise in after-hours trading following insider purchases. Director John Livingston bought 26.3K shares for $247K on September 14.

15 set 2026, 23:06 UTC

News

Apple Inc. shares rose in after-market trading following a product event that introduced new offerings and received an "Overweight" rating from Morgan Stanley with a $360 target.

15 set 2026, 23:06 UTC

Correlated Moves
News

Blackstone Inc's shares are higher in after-market trading, likely influenced by KKR & Co Inc's recovery and recent IPO activity highlighted by CFO Michael Chae.

15 set 2026, 23:06 UTC

News

UnitedHealth Group will release third quarter 2026 results on October 13. Shares are trading higher in after-market hours, reflecting a modest gain.

15 set 2026, 23:06 UTC

News

Intuit Inc reported full-year revenue of $21.4 billion, a 14% increase. Shares are higher in after-market trading following the results and positive sentiment.

15 set 2026, 23:02 UTC

News

Walmart shares rose in after-market trading following a 5.1% growth in global enterprise, surpassing its average target and reflecting strong consumer spending.

15 set 2026, 23:02 UTC

News

Permian Resources shares are higher in after-market trading, with a current price of $24.49, reflecting strong long-term performance and a market cap of $20.51 billion.

15 set 2026, 23:02 UTC

News
Social Media

RTX shares are higher in after-market trading following the appointment of Jill Albertelli as president of Pratt & Whitney, effective January 1, 2027.

15 set 2026, 23:02 UTC

Correlated Moves
News

Chevron Corp shares are lower in after-market hours, influenced by a drop in the New York Empire State Manufacturing Index and ongoing supply risks.

15 set 2026, 23:02 UTC

News
Event

Trip.com Group Ltd reported second-quarter EPS of $1.07, exceeding expectations, while shares rose in after-market trading following the earnings announcement.

15 set 2026, 23:02 UTC

News

Target Corp shares are trading higher in after-market hours following the announcement of a new employee apparel line designed by Isaac Mizrahi.

15 set 2026, 23:02 UTC

Social Media
News

Celsius Holdings Inc. shares rose in after-hours trading following significant insider purchases totaling around $1 million by Director Damon DeSantis.

15 set 2026, 23:02 UTC

Correlated Moves
News

Qualcomm's after-market trading remains stable, reflecting Nasdaq 100 trends. The company reported $9.9 billion in revenue for the fiscal third quarter.

15 set 2026, 23:02 UTC

News

CrowdStrike Holdings shares are lower in after-market hours amid negative sentiment following a sharp decline in the New York Empire State Manufacturing Index.

15 set 2026, 23:02 UTC

News

Radiant Logistics shares are higher in after-market trading despite Glencore's $2 billion lawsuit alleging fraud and terminating business relationships with Radiant World.

15 set 2026, 23:02 UTC

Correlated Moves
News

Coinbase Global shares are lower in after-hours trading, influenced by declines in Bitcoin and Bitmine Immersion Technologies, amid a weak overall trading environment.

15 set 2026, 23:01 UTC

News

Boeing's recent Pentagon agreements include a $13.4 billion expansion of the KC-46 contract, though shares traded roughly flat in after-market hours.

15 set 2026, 23:01 UTC

News
Event

Evolution Petroleum shares are higher after reporting fourth-quarter revenue of $24.21 million, exceeding expectations, though adjusted EPS missed consensus estimates.

15 set 2026, 23:01 UTC

News

Interactive Brokers Group has integrated with X Cashtags, enabling US users to trade directly from tagged stock and crypto symbols. Shares are higher in after-market hours.

15 set 2026, 23:01 UTC

News

D.R. Horton announced a $5 billion stock repurchase program and raised its fiscal 2026 buyback target to $3.25 billion, contributing to after-market gains.

15 set 2026, 23:01 UTC

News

Alignment Healthcare Inc. shares are lower in after-market hours as bipartisan lawmakers introduce the Protecting Approved Care Act, impacting Medicare Advantage plans.

15 set 2026, 23:01 UTC

News

Coca-Cola Co plans a $10 billion investment in U.S. infrastructure by 2030. Shares showed little change during after-market hours, reflecting stable trading conditions.

Confronto tra pari

Modifica del prezzo

Hutchison China MediTech Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

18.35% in crescita

Previsioni per 12 mesi

Media 16.167 USD  18.35%

Alto 18.5 USD

Basso 14 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Hutchison China MediTech Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

3 ratings

2

Acquista

1

Mantieni

0

Vendi

Sentiment

By Acuity

129 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat